Cambridge Healthtech Institute’s 5th Annual
Machine Learning for Protein Engineering Part 2
Demonstrating Value and Putting Theory into Practice
19 November 2026
Cambridge Healthtech Institute's fifth-annual Machine Learning for Protein Engineering Part 2 conference at PEGS Europe examines and measures the real impact of using AI/ML techniques by developing benchmarks, standards, and controls to guide the process of incorporating these tools throughout the drug discovery and development workflow. Case studies of implementation will be reviewed, including discovery, optimisation, prediction, developability assessment, and simulation of biologics.
Coverage will include, but is not limited to:
- Reviewing system-wide incorporation of AgenticAI, ESM3 models, and protein language models
- Case studies of incorporating generative AI and ML into the drug-discovery pipeline
- Recent advances in de novo design: Applications and comparisons against traditional discovery approaches
- Evolving multimodal models
- Designing the next series of benchmarking challenges
- Addressing difficult targets and uncharacterised targets/domains with AI/ML
- Employing AI/ML for designing smart biologics: i.e., logic-gated, pH-activated, and masked
- Targeting undruggable pockets with AI/ML
The deadline for priority consideration is 26 March 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: